Immunic Therapeutics

❓ 3 questions to our new Chief Medical Officer ❓ We asked Michael Panzara, M.D., M.P.H., why he joined Immunic, what stands out in our development pipeline, and where unmet needs in multiple sclerosis (MS) remain most pressing. 👉 Explore his perspective. #IMUX #ManagementPerspectives #Neurology

🔬 #ClinicalTrialsDay: Clinical trials are at the core of medical progress. At Immunic, our work in multiple sclerosis is guided by scientific curiosity and a shared commitment to improving outcomes for patients. We sincerely thank everyone participating in and contributing to our clinical research: the patients and their families, investigators, site staff and our clinical teams. Your commitment and collaboration make this work real and progress would not be possible without you. 💙 ACRP - Association of Clinical Research Professionals #CTD2026 #ResearchRising #IMUX

🧭 Board update at Immunic: Michael W. Bonney has been appointed new Chair of our Board of Directors. 🧠 With more than three decades of experience in the biopharmaceutical industry, including deep expertise in multiple sclerosis (MS) and central nervous system (CNS) markets, Mike brings valuable perspectives as we advance our clinical programs and prepare for upcoming milestones. His background spans senior leadership roles at Biogen, including for the launch and commercial success of MS drug Avonex®, as well as CEO of Cubist Pharmaceuticals and roles of increasing responsibility at Zeneca Pharmaceuticals. His strong experience further strengthens our Board as we continue to advance our phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) and plan to initiate a confirmatory phase 3 program in primary progressive multiple sclerosis (PPMS). We also thank Simona Skerjanec for her dedicated leadership as Interim Chairperson and her continued role on our Board. 🙏 Get all the details here: https://bit.ly/4uWM1wW #IMUX 

Halfway point at May 50K! 💪 The #IMUX team is off to a strong start with 800 km already logged. Let’s keep the momentum going – every step, ride, swim, and roll counts. There is still time to sign up and get active: 👉 https://www.themay50k.de DMSG - Deutsche Multiple Sklerose Gesellschaft, Bundesverband e.V., MS Society, Stichting MS Research, MS International Federation (MSIF), Multiple Sclerosis Ireland, #May50K #MSAwareness #MoveForMS #ImmunicInMotion #Immunic

Q1 Update: Setting the Course for 2026 📈 Yesterday, we reported our first quarter 2026 financial results and a corporate update, highlighting continued progress across our clinical development pipeline, the appointment of our new Chief Medical Officer, and a strengthened financial position. 🎥 Our CEO Dr. Daniel Vitt spoke with Proactive about the recent updates and what lies ahead for #Immunic. Watch the full interview here: https://bit.ly/4dj6Wmy #biotechnology #immunology #IMUX

Today, we reported our first quarter financial results and a provided a corporate update. Key highlights include: 📣 Appointed globally renowned biopharmaceutical executive and neurology drug developer, Michael Panzara, M.D., M.P.H., as Chief Medical Officer 🚀 Continued to execute phase 3 ENSURE trials of vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (MS, RMS), with top-line data expected by end of 2026 📈 Raised $200 million in an oversubscribed private placement, with potential for up to an additional $200 million 👉 Get all the details here: https://bit.ly/3PAkceI #Immunic #IMUX #IMU838 #MSResearch #biotech #healthcare

🧩 Treating symptoms is one piece of the puzzle. Targeting underlying disease biology is another. 🎙️ On the Base to Base Biotech podcast, our CEO Dr. Daniel Vitt joined host Jim Cornall for a wide‑ranging discussion on Immunic, our focus on neurologic diseases, the science behind our clinical and preclinical programs, and the challenges of developing therapies that aim beyond symptom control. 🎧 Listen to the full episode to hear what lies ahead for Immunic and for the patients we are working to support: https://bit.ly/48MhVna #IMUX #vidofludimus #IMU838 #neurology #MultipleSclerosis #MS

Tomorrow, the Clinical Trial Supply Forum kicks off in Amsterdam, bringing together experts to exchange perspectives on how clinical supply chains can better support increasingly complex trials. 🌍 Our colleague Kimi Le, Global Head of Clinical Trial Supply, will contribute to the program with a case study tomorrow, May 12 (12:15-12:45 CEST), sharing perspectives on strategies for clinical supply success and the role of strong sponsor-vendor partnerships. She will also take part in a panel discussion later in the day focused on emerging technologies shaping the future of clinical trial supplies. 🔬 Looking forward to thoughtful discussions and shared learnings over the coming days in Amsterdam. 🇳🇱 Pharma IQ #Immunic #IMUX

🎗️ We appreciated the opportunity to attend the 12th MSAA Improving Lives Benefit Gala last week and support the important work of the Multiple Sclerosis Association of America (MSAA). Being there together with our new medical affairs team reflected the importance of staying closely connected with the multiple sclerosis (MS) community as we move through a meaningful year for Immunic. 🧡 #IMUX #vidofludimus #IMU838 #RaisingAwareness

Two days of insightful dialogue at BioEquity Europe 🇪🇺 🤝 Our CEO, Dr. Daniel Vitt, and VP Investor Relations & Communications, Jessica Breu, appreciated the many 1:1 conversations with investors and industry peers – reconnecting with familiar faces and meeting new ones. 🙏 Thank you to BioCentury Inc., Informa Connect and EBD Group for hosting a great event in Prague 🇨🇿. We look forward to next year’s edition in Copenhagen 🇩🇰. #IMUX #Networking #BioEquityEurope #EBDGroup